Shanghai RAAS Blood Products Co Ltd Class A (002252) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Shanghai RAAS Blood Products Co Ltd Class A stock ¥3.75, price ¥4.94, that is 24.1% below the price, quality 51 out of 100. Rating: overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range ¥4.31 – ¥8.27 · fair‑value band ¥3.31 – ¥5.77 · the ¥4.94 price screens above the ¥3.75 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 5, 2026.
Follow Shanghai RAAS Blood Products Co Ltd Class A in your weekly email
Every Wednesday you see whether Shanghai RAAS Blood Products Co Ltd Class A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally.
Show moreShow less
The company offers ALBURAAS, which is albumin prepared from human plasma; GAMARAAS, a human immunoglobulin product for intravenous injections; HEMORAAS, a human coagulation factor VIII product; PROTHORAAS, a human prothrombin complex; FIBRORAAS, a human fibrinogen; FIBINGLURAAS, a fibrin sealant for humans; and THROMBIRAAS, a human thrombin product.
It also provides specific immune, human tetanus immunoglobulin, human rabies immunoglobulin, human immunoglobulin, hepatitis B human immunoglobulin, and other blood products. The company exports its products.
Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is headquartered in Shanghai, China.
Stock analysis
Shanghai RAAS Blood Products Co Ltd Class A (002252) currently trades at ¥4.94, while our model-based Fair Value estimate is ¥3.75, 24% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥6.56 per share, and 4 of the 17 models we run sit above the ¥4.94 price.
Bear case: the Asset-Based group reads lowest at ¥0.7000, and 13 of the 17 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥3.31 (bear) to ¥5.77 (bull), the price of ¥4.94 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Shanghai RAAS Blood Products Co Ltd Class A reported revenue of 7.3B CNY in FY2025 versus 4.3B CNY in FY2021, a compound +14.4%/yr. Reported net income was 1.6B CNY in FY2025, compounding +5.1%/yr from FY2021.
Key figures
Market cap 32.5B CNY (≈ $4.9B) Mid · P/E ratio 29.1 · P/S ratio 5.23 · EPS (TTM) ¥0.1700 · Dividend yield 0.7% · Net margin 17.5% · Return on equity 3.3% · Return on assets (EBIT) 6.6% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 28% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −24%, 002252 screens richer than that median.
Fair Value models
Bear¥3.31Fair Value ¥3.75Bull¥5.77
Price ¥4.94 · Downside -24.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.1171 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.57/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−10.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.6%
Start year 2020 (pandemic). Over 10 years: +13.8% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+5.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.6%
Dividend (yield on the price)0.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.4.6% vs −1.9%, picking up
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.29% → 26%
Compare Shanghai RAAS Blood Products Co Ltd Class A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score51 · Above median
Fair Value upside−24.1% · Above median
Profitability
Return on equity (12 months)3.3% · Above median
Return on assets4.2% · Top 25%
Net margin (12 months)17.5% · Above median
Operating margin (12 months)19.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)−18.9% · Bottom 25%
Dividend yield (12 months)0.7% · Below median
Balance sheet
Debt / equity0.08× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shanghai RAAS Blood Products Co Ltd Class A Fair Value". https://www.fairvalue-calculator.com/stock/002252
Frequently asked questions
Is Shanghai RAAS Blood Products Co Ltd Class A (002252) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of ¥3.75 versus a price of ¥4.94, about 24% lower (overvalued).
What is the fair value of 002252?
Our model-based fair value for Shanghai RAAS Blood Products Co Ltd Class A is ¥3.75 (as of Nov 5, 2026), built from audited fundamentals. The current price: ¥4.94.
What is the quality score of 002252?
Shanghai RAAS Blood Products Co Ltd Class A has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai RAAS Blood Products Co Ltd Class A (002252)?
Our model-based price target is the fair value of ¥3.75 (as of Nov 5, 2026) from 17 valuation models. Cautious scenario ¥3.31, optimistic scenario ¥5.77. It is a calculation from audited fundamentals, not an analyst target.
What is the Shanghai RAAS Blood Products Co Ltd Class A stock forecast for 2026?
Our models put fair value at ¥3.75, about 24% lower versus a price of ¥4.94 (overvalued). Cautious scenario ¥3.31, optimistic scenario ¥5.77. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai RAAS Blood Products Co Ltd Class A (002252)?
Shanghai RAAS Blood Products Co Ltd Class A reported trailing-twelve-month revenue of about 6.2B CNY (latest available figure, as of Nov 5, 2026).
Does Shanghai RAAS Blood Products Co Ltd Class A pay a dividend?
Shanghai RAAS Blood Products Co Ltd Class A currently shows a dividend yield of 0.67% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Shanghai RAAS Blood Products Co Ltd Class A (002252) and when is the ex-dividend date?
Shanghai RAAS Blood Products Co Ltd Class A pays a dividend of ¥0.033 per share a year, a dividend yield of 0.7%. The last ex-dividend date was Jun 24, 2026. A dividend has been paid every year since 2020. The payout ratio is 19.4% of earnings. Our assessment: Token dividend. At a yield of 0.7% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.7% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Shanghai RAAS Blood Products Co Ltd Class A (002252)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai RAAS Blood Products Co Ltd Class A it is ¥3.75 per share (as of Nov 5, 2026), against a price of ¥4.94. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Shanghai RAAS Blood Products Co Ltd Class A stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 002252 trades above its calculated fair value: price ¥4.94, fair value ¥3.75, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002252?
No. The price is what the market pays today (¥4.94); the fair value is what the company's own numbers justify (¥3.75). For Shanghai RAAS Blood Products Co Ltd Class A the two are ¥1.19 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai RAAS Blood Products Co Ltd Class A worth?
The market values Shanghai RAAS Blood Products Co Ltd Class A at about 32.5B CNY (market capitalisation, as of Nov 5, 2026). Per share that is ¥4.94; our models calculate a fair value of ¥3.75 per share.
What do the bullish and bearish scenarios say about 002252?
Our models span a range for Shanghai RAAS Blood Products Co Ltd Class A: cautious scenario ¥3.31, base ¥3.75, optimistic ¥5.77 per share (as of Nov 5, 2026, price ¥4.94). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 002252?
Shanghai RAAS Blood Products Co Ltd Class A trades at a price-to-earnings ratio of 29.1 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥3.75 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings: 35.5. Other multiples: P/B 1.0, P/S 5.2, EV/EBITDA 26.7.
How solid is the balance sheet of Shanghai RAAS Blood Products Co Ltd Class A (002252)?
Balance-sheet figures for Shanghai RAAS Blood Products Co Ltd Class A (as of Nov 5, 2026): return on equity 3.3%, debt of 0.08 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is 002252 from its 52-week high?
Shanghai RAAS Blood Products Co Ltd Class A trades at ¥4.94, about 28% below its 52-week high of ¥6.86 and 15% above the low of ¥4.31 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥3.75 is for.
Which stocks are comparable to Shanghai RAAS Blood Products Co Ltd Class A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai RAAS Blood Products Co Ltd Class A stock attractive at the current price?
The data as of Nov 5, 2026: price ¥4.94, calculated fair value ¥3.75 (−24%), Quality Score 51/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002252 calculated?
We run Shanghai RAAS Blood Products Co Ltd Class A through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥3.75 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Shanghai RAAS Blood Products Co Ltd Class A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai RAAS Blood Products Co Ltd Class A (002252)?
The closing price on Nov 6, 2026 was ¥4.94. Our model-based fair value is ¥3.75, about 24% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai RAAS Blood Products Co Ltd Class A right now?
Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Shanghai RAAS Blood Products Co Ltd Class A (002252) come from?
Earnings per share at Shanghai RAAS Blood Products Co Ltd Class A grew +1.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +12.7 %, EBIT margin −10.1 %, tax rate −0.2 %, residual (interest, one-offs) +0.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Shanghai RAAS Blood Products Co Ltd Class A
How large is the market capitalisation of Shanghai RAAS Blood Products Co Ltd Class A (002252)?
The market capitalisation of Shanghai RAAS Blood Products Co Ltd Class A is 32.5B CNY (≈ $4.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shanghai RAAS Blood Products Co Ltd Class A (002252)?
The price-to-sales ratio of Shanghai RAAS Blood Products Co Ltd Class A is 5.23 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shanghai RAAS Blood Products Co Ltd Class A (002252)?
Earnings per share at Shanghai RAAS Blood Products Co Ltd Class A are ¥0.1700 (price ÷ EPS = P/E 29.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shanghai RAAS Blood Products Co Ltd Class A (002252)?
The dividend yield of Shanghai RAAS Blood Products Co Ltd Class A is 0.7% (payout 19.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shanghai RAAS Blood Products Co Ltd Class A (002252)?
The net margin of Shanghai RAAS Blood Products Co Ltd Class A is 17.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shanghai RAAS Blood Products Co Ltd Class A (002252)?
The return on equity (ROE) of Shanghai RAAS Blood Products Co Ltd Class A is 3.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai RAAS Blood Products Co Ltd Class A (002252)?
On an EBIT basis the return on assets of Shanghai RAAS Blood Products Co Ltd Class A is 6.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai RAAS Blood Products Co Ltd Class A (002252)?
The operating margin of Shanghai RAAS Blood Products Co Ltd Class A is 19.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai RAAS Blood Products Co Ltd Class A (002252)?
Revenue at Shanghai RAAS Blood Products Co Ltd Class A is growing −18.9% versus a year earlier (3y avg +3.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shanghai RAAS Blood Products Co Ltd Class A (002252)?
Earnings per share at Shanghai RAAS Blood Products Co Ltd Class A are growing −28.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Shanghai RAAS Blood Products Co Ltd Class A (002252) generate?
The free cash flow of Shanghai RAAS Blood Products Co Ltd Class A is −484M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Shanghai RAAS Blood Products Co Ltd Class A (002252) carry?
The net debt of Shanghai RAAS Blood Products Co Ltd Class A is 2.6B CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Shanghai RAAS Blood Products Co Ltd Class A in the live analysis
One click puts Shanghai RAAS Blood Products Co Ltd Class A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026